GLP1R and obesity disorder: Nonetheless, in a previous study by our group [9], intensification of LIRA dose did not correlate with a greater decrement in HbA1c at 5-year follow-up in patients with T2D and overweight/obesity; therefore, the question about which GLP-1 RAs has higher potency and durability in controlling hyperglycemia under these circumstances remains an open one [29].